Vanguard Capital Management Takes 7.5% Passive Stake in Hologic, Files 13G

Vanguard Capital Management LLC, along with its affiliated entities, reported holding 16,721,923 shares of Hologic Inc. (HOLX)—equating to 7.49% of the company’s outstanding common stock. The filing, made under Rule 13d‑1(b) as a Schedule 13G, classifies Vanguard as a passive institutional investor, meaning it does not intend to influence corporate governance or pursue activist strategies.

The filing details that Vanguard exercises sole voting power on 2,218,009 shares and sole dispositive power on the full 16,721,923 shares, with no shared voting or dispositive rights. The stakes are held through a suite of Vanguard funds and affiliates, including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd., all under Vanguard Capital Management’s control.

For Hologic shareholders, the disclosure is largely a reaffirmation of confidence rather than a catalyst for change. The company’s stock is trading at $76.01, up 0.48% on the day, while the broader S&P 500 rose 0.90%. Hologic’s relative strength index (RSI) sits at 77, indicating the stock is in overbought territory, and its market cap stands at $17.0 billion. The modest price uptick aligns with the broader market’s positive momentum, suggesting the Vanguard filing is being absorbed as a routine, albeit noteworthy, institutional endorsement.

No other party is known to hold a beneficial interest exceeding 5% of Hologic’s common stock, and the filing does not list any additional owners of 5% or less. As a passive holder, Vanguard is unlikely to file a more detailed Schedule 13D unless its investment thesis evolves toward active engagement.

Overall, the 13G filing underscores Vanguard’s continued accumulation of high‑quality health‑care assets, while offering existing investors a glimpse into the growing institutional appetite for Hologic’s diagnostic and medical‑device portfolio.